Literature DB >> 12407295

Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia.

G Stoll1.   

Abstract

Cytokines are immune mediators that orchestrate inflammatory responses. In autoimmune disorders of the nervous system such as the Guillain-Barré syndrome (GBS), and the corresponding animal model, experimental autoimmune neuritis (EAN), proinflammatory cytokines augment nerve infiltration by T-cells and contribute to macrophage-mediated demyelination. The local balance between pro- and antiinflammatory effects determines the clinical course. Cytokine expression in the nervous system is, however, not restricted to autoimmune disorders. Cytokines likewise contribute to infarct growth after focal cerebral ischemia, and under certain conditions convey neuroprotection. This short review summarizes selected aspects of cytokine actions during immune-mediated demyelination and cerebral ischemia. Elucidation of cytokine-mediated pathways of neurotoxicity and neuroprotection may not only improve stroke treatment, but, in addition may have a major impact on autoimmune diseases such as multiple sclerosis and GBS, in which axonal loss rather than demyelination determines long-term disability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407295

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  14 in total

1.  Guillain-Barré syndrome after rtPA therapy for acute stroke.

Authors:  A Bersano; D Santoro; A Prelle; S Lanfranconi; M Ranieri; C S Tadeo; N Bresolin; P L Baron
Journal:  Neurol Sci       Date:  2010-05-08       Impact factor: 3.307

2.  Immunochemical composition of cryoglobulins generated in stroke.

Authors:  Levon Manukyan; Anna Boyajyan; Arsen Arakelyan; Violetta Ayvazyan; Elina Arakelova; Robert Sim; George Grigoryan
Journal:  J Clin Immunol       Date:  2008-11-04       Impact factor: 8.317

3.  TLR2 ligand induces protection against cerebral ischemia/reperfusion injury via activation of phosphoinositide 3-kinase/Akt signaling.

Authors:  Chen Lu; Li Liu; Yuling Chen; Tuanzhu Ha; Jim Kelley; John Schweitzer; John H Kalbfleisch; Race L Kao; David L Williams; Chuanfu Li
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

Review 4.  Integration of cytokine biology and lipid metabolism in stroke.

Authors:  Rao Muralikrishna Adibhatla; Robert Dempsy; James Franklin Hatcher
Journal:  Front Biosci       Date:  2008-01-01

5.  Systemic complement activation following human acute ischaemic stroke.

Authors:  E D Pedersen; U Waje-Andreassen; C A Vedeler; G Aamodt; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

6.  Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice.

Authors:  Fang Hua; Jing Ma; Tuanzhu Ha; Jim L Kelley; Race L Kao; John B Schweitzer; John H Kalbfleisch; David L Williams; Chuanfu Li
Journal:  Brain Res       Date:  2009-01-22       Impact factor: 3.252

Review 7.  Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression.

Authors:  H Offner; A A Vandenbark; P D Hurn
Journal:  Neuroscience       Date:  2008-07-01       Impact factor: 3.590

8.  T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation.

Authors:  Patricia D Hurn; Sandhya Subramanian; Susan M Parker; Michael E Afentoulis; Laurie J Kaler; Arthur A Vandenbark; Halina Offner
Journal:  J Cereb Blood Flow Metab       Date:  2007-03-28       Impact factor: 6.200

9.  The TRIF-dependent signaling pathway is not required for acute cerebral ischemia/reperfusion injury in mice.

Authors:  Fang Hua; Jun Wang; Iqbal Sayeed; Tauheed Ishrat; Fahim Atif; Donald G Stein
Journal:  Biochem Biophys Res Commun       Date:  2009-10-13       Impact factor: 3.575

10.  Poly (I:C) therapy decreases cerebral ischaemia/reperfusion injury via TLR3-mediated prevention of Fas/FADD interaction.

Authors:  Xia Zhang; Tuanzhu Ha; Chen Lu; Fred Lam; Li Liu; John Schweitzer; John Kalbfleisch; Race L Kao; David L Williams; Chuanfu Li
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.